Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Company Overview
Harrow Health Inc (HROW) is an innovative eyecare pharmaceutical company focused on addressing unmet medical needs through the discovery, development, production, and commercialization of specialized ophthalmic formulations and therapeutic products across the United States. Operating at the intersection of advanced research and clinical application, the company brings together deep industry expertise, rigorous R&D, and a commitment to improving patient care.
Business Model and Operations
At its core, Harrow Health provides a comprehensive portfolio that blends ophthalmology-based drug development with non-intravenous sedation and anesthesia therapeutics for a variety of medical procedures. Its operations are structured around:
- Ophthalmic Therapeutics: Focusing on the management of ocular surface diseases, the company develops topical eye drop formulations that serve both preventative and therapeutic roles.
- Compounded Medications: Offering both sterile and non-sterile formulations, it meets the needs of physicians seeking tailored solutions for diverse clinical scenarios.
- Non-Intravenous Sedation: Developing products designed to facilitate conscious sedation during procedures such as cataract surgery, thereby enhancing patient comfort and procedural efficiency.
This multi-pronged approach not only diversifies its product portfolio but also creates a resilient business model that appeals to healthcare professionals and institutions across outpatient, in-office, and hospital settings.
Market Position and Competitive Landscape
Harrow Health Inc has carved a niche within the highly regulated US pharmaceutical market. Its strategic focus on ocular and sedation therapeutics differentiates it from broader scale pharmaceutical companies, while its commitment to advanced research and quality production standards reinforces its reputation among eyecare professionals. In a competitive landscape where precision and safety are paramount, Harrow Health’s integration of clinical insights with innovative drug formulations positions it as a noteworthy player devoted to addressing specific medical challenges effectively.
Product Portfolio and Therapeutic Solutions
The company has developed an extensive range of products that address conditions related to the ocular surface and procedural sedation. Its portfolio includes:
- Topical Ophthalmic Formulations: Designed to manage diseases affecting the ocular surface and support rehabilitation of vision-related functions.
- Compounded Medications: Both sterile and non-sterile, these are tailored to meet precise medical requirements across various treatment settings.
- Sedation Therapeutics: Products intended for sublingual administration provide non-intravenous sedation, enabling safe and effective patient management during surgical procedures.
Research, Development, and Quality Assurance
The foundation of Harrow Health Inc’s operations lies in robust research and development. The company continually refines its product offerings through comprehensive clinical research and adherence to stringent quality assurance protocols. Its approach underscores a commitment to safety and efficacy while addressing the evolving needs of healthcare providers and patients. This rigorous scientific methodology exemplifies the company’s dedication to maintaining high standards of regulatory compliance and industry best practices.
Commitment to Scientific Integrity and Patient Care
Across its diverse operations, Harrow Health demonstrates a sustained commitment to improving patient outcomes. The company’s emphasis on continuous innovation, strategic R&D, and quality-focused manufacturing processes helps ensure that its pharmaceutical solutions not only meet but often exceed industry benchmarks. This dedication to scientific integrity and patient well-being has established Harrow Health as a trusted entity within the field of eyecare therapeutics.
Strategic Value Proposition
Harrow Health Inc’s value proposition is rooted in its specialized expertise in ophthalmic formulations and sedation therapies. By addressing critical gaps in current medical treatments, the company supports healthcare providers in delivering effective and accessible care. Its balanced focus on innovation, quality, and clinical relevance positions it as a vital contributor to the pharmaceutical landscape, particularly within the realms of eye care and procedural sedation.
Overall, Harrow Health Inc exemplifies a dedicated, research-driven approach to pharmaceutical development that leverages deep industry expertise to meet unmet medical needs. Through its integrated operations and commitment to quality, it remains a significant, unbiased source of therapeutic solutions for healthcare professionals nationwide.
Harrow Health, Inc. (NASDAQ: HROW) reported record financial results for Q2 and H1 ended June 30, 2021, marking its best quarter ever with significant growth in revenues, cash flow from operations, and Adjusted EBITDA. The company raised $75 million in unsecured capital, which is being utilized for strategic initiatives, including the acquisition of AMP-100, an ophthalmic anesthetic drug candidate, with an FDA application expected soon. Harrow anticipates a strong second half of 2021, aimed at enhancing product diversity and operational performance.
Harrow Health (NASDAQ: HROW) has entered an agreement with Sintetica, S.A. to acquire marketing and supply rights for AMP-100, an innovative ophthalmic surgical drug candidate for ocular surface anesthesia. This acquisition targets a market with over 10 million procedures annually in the U.S. AMP-100's safety and efficacy are backed by a comprehensive clinical program and a successful Phase 3 study. Sintetica plans to submit a New Drug Application to the FDA in late 2021. Harrow aims to leverage its commercial platform to maximize AMP-100's market potential.
Harrow Health, Inc. (NASDAQ: HROW) announced the release of its financial results for Q2 and six months ended June 30, 2021, scheduled for August 10, 2021, post-market. The company will share its second-quarter letter to stockholders on its website. A conference call and live webcast will follow at 4:45 PM ET to discuss results and provide a business update. Harrow Health is focused on ophthalmology, operating ImprimisRx and Visionology, and holds equity positions in Eton Pharmaceuticals, Surface Ophthalmics, and Melt Pharmaceuticals.
NovaBay Pharmaceuticals (NYSE American: NBY) has partnered with ImprimisRx, a subsidiary of Harrow Health (Nasdaq: HROW), for the promotion of its product Avenova, a 0.01% hypochlorous acid solution for eye care. This collaboration aims to enhance national sales, marketing, and distribution efforts for Avenova, which addresses chronic eye conditions affecting 30 million Americans. The partnership is expected to improve accessibility to prescription Avenova through a streamlined pharmaceutical model.
Harrow Health, Inc. (NASDAQ: HROW) announced two newly issued patents related to ophthalmic compositions for intraocular administration. These patents, dated May 4 and June 29, 2021, enhance Harrow's portfolio in surgical dilation agents, particularly for cataract surgeries. Data regarding a compounded mydriatic drug combination will be presented at the ASCRS 2021 Annual Meeting, demonstrating effective pupil dilation. This advancement positions Harrow Health for growth within the ophthalmic market, supporting over 250,000 cataract procedures annually.
Harrow Health (NASDAQ: HROW) announced the closure of its public offering, raising $20 million through the issuance of 8.625% senior notes due 2026. This includes a $2.5 million over-allotment option. The net proceeds of approximately $19.6 million will be used to redeem Series B Cumulative Preferred Stock and for general corporate purposes, including future product acquisitions. The notes, rated "BB" by Egan-Jones Ratings, will trade on Nasdaq under the symbol 'HROWL'.
Harrow Health (NASDAQ: HROW) has priced its underwritten public offering of $17.5 million in 8.625% senior notes due 2026. The offering, expected to close on June 17, 2021, may increase by $2.5 million if the underwriters exercise their option. The notes will be priced at $25.75 each, yielding aggregate proceeds of $18,025,000. Proceeds will be utilized to redeem Series B Cumulative Preferred Stock and support general corporate purposes. Both the new and existing notes are rated 'BB' by Egan-Jones Ratings Company and will trade on Nasdaq under the symbol 'HROWL'.
Harrow Health (NASDAQ: HROW) has initiated an underwritten registered public offering of $17.5 million in 8.625% senior notes due 2026. These notes will trade alongside the existing notes of the same series. The proceeds are intended to redeem all outstanding Series B Cumulative Preferred Stock and for general corporate purposes, including product acquisitions and capital expenditures. Harrow Health's notes received a 'BB' rating from Egan-Jones Ratings Company. The offering will be conducted under the effective shelf registration statement filed with the SEC.
Harrow Health (NASDAQ: HROW), an ophthalmic-focused healthcare company, has launched a redesigned corporate and investor website aimed at enhancing user experience and accessibility of historical and current information. The site showcases Harrow's journey as a leading eye health provider, featuring its mission, product pipeline, and commitment to accessible eyecare. Key assets include ImprimisRx and Visionology, along with equity stakes in several pharmaceutical companies. The site also includes Letters to Stockholders and a Corporate Presentation to facilitate investor engagement.
Harrow Health, Inc. (NASDAQ: HROW) announced a multi-center retrospective study demonstrating significant improvements in patients with dry eye disease using its Klarity-C Drops® (cyclosporine 0.1%). Published in Clinical Ophthalmology, the study involved 50 patients and showed a marked decrease in ocular surface disease index (OSDI) scores and corneal staining grades after three months of treatment. The study highlighted no adverse events and emphasized Klarity-C's advantages over existing treatments, including its affordability and lack of insurance hurdles.
FAQ
What is the current stock price of Harrow Health (HROW)?
What is the market cap of Harrow Health (HROW)?
What is Harrow Health Inc's primary focus?
What types of products does the company offer?
How does Harrow Health Inc generate revenue?
What differentiates Harrow Health from its competitors?
In which market does Harrow Health primarily operate?
What role does research and development play in the company?
How does the company support clinical practices?
Can you explain the company’s approach to quality assurance?
